Market Intelligence, Clinical Progress, and High-Purity Reagents for Cancer Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TRIP13 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TRIP13 Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for ATPase activity assays. |
View TRIP13 Products |
| Gene Delivery | TRIP13 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression studies. |
View TRIP13 Products |
| Benchmark Ab | Anti-TRIP13 Recombinant Antibody High-specificity positive control for Western Blot, IHC, and ELISA. |
View TRIP13 Products |
| Validator | TRIP13 siRNA Set For knockdown verification and functional rescue assays. |
View TRIP13 Products |
| Related Target A | MAD2L1 (MAD2) Direct functional partner in the spindle assembly checkpoint (SAC) pathway. |
View MAD2L1 Products |
| Related Target B | MAD2L1BP (p31comet) Adapter protein mediating TRIP13-induced inactivation of the SAC. |
View MAD2L1BP Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| ATPase Activity Quantification | High-purity recombinant TRIP13 with confirmed theoretical molecular weight and low endotoxin levels, optimized for ADP-Glo assays. |
| Off-target Screening (AAA+ ATPases) | Homolog panel screening proteins (e.g., VCP/p97, NSF) strictly verified by mass spectrometry to ensure inhibitor selectivity. |
| Lack of Controls | Clinical-grade recombinant benchmark antibodies and sequence-verified siRNA sets included in the assay validation package. |
| False Positives in High-Throughput Screening | Highly pure, E. coli or eukaryotic-expressed proteins minimizing bacterial ATPase contamination. |
Live TRIP13 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TRIP13 therapeutics is intensifying, with major players shifting focus from traditional oncology targets to mitotic checkpoint regulators. As an AAA+ ATPase responsible for dismantling the mitotic checkpoint complex (MCC) by converting C-MAD2 to O-MAD2, TRIP13 has emerged as a key driver of chromosomal instability and drug resistance. The next wave of R&D is targeting small-molecule covalent inhibitors and PROTAC-mediated degradation to overcome resistance to proteasome inhibitors (e.g., bortezomib) and microtubule-stabilizing agents.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Academic consortia, Biotech startups | Multiple Myeloma, Colorectal Cancer, Breast Cancer | High-throughput ATPase assays (Need active, contaminant-free recombinant TRIP13) |
| PROTAC / Degrader | Targeted Protein Degradation (TPD) specialists | Refractory Solid Tumors, Hematological Malignancies | Ternary complex formation assays (Need high-purity TRIP13, MAD2L1BP, and MAD2L1 proteins) |
| RNA Therapeutics | Oligonucleotide therapeutics developers | Advanced Stage Glioblastoma, Epithelial Cancers | In vitro knockdown validation (Need sequence-verified TRIP13 siRNA sets) |